ASCO 2019: Phase II COLET study: First-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (mTNBC)

Adam Brufsky | ASCO 2019 | Juni 5, 2019

Speaker: Adam Brufsky

In the COLET study Adam Brufsky et al investigated the efficacy and safety of Atezolizumab + cobimetinib + paclitaxel/nab-paclitaxel as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (mTNBC). This combination may target multiple cancer immune escape mechanisms simultaneously. Hear Adam Brufsky present the results.